Erasca announced an oral presentation of preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations at the 36th EORTC-NCI-AACR, ENA, Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
- Erasca participates in a conference call with JPMorgan
- Erasca price target raised to $6 from $5 at H.C. Wainwright
- Erasca Reports Second Quarter 2024 Business Updates and Financial Results
- Erasca reports Q2 EPS (29c), consensus (18c)